title: Risks of immunodeficiency, AIDS, and death related to purity of factor VIII concentrate. Multicenter Hemophilia Cohort Study.
abstract: In HIV-infected subjects with haemophilia, CD4 counts seem to fall more slowly in those on high-purity factor VIII (FVIII) than on intermediate-purity product. We evaluated whether risks for AIDS or death were associated with either product among 411 HIV-infected individuals. The relative hazard of AIDS was slightly elevated for both current (1.34) [corrected] and cumulative (1.01 per month) use of high-purity products (neither significant). The corresponding hazards for death were 1.49 and 1.03 (neither significant). Thus we found no evidence that high-purity FVIII concentrates retard the development of AIDS.
authors.affiliation: AIDS and Cancer Section, Viral Epidemiology Branch, National Cancer Institute, Rockville, Maryland.
authors.forename: J J
authors.initials: JJ
authors.lastname: Goedert
authors.forename: A R
authors.initials: AR
authors.lastname: Cohen
authors.forename: C M
authors.initials: CM
authors.lastname: Kessler
authors.forename: S
authors.initials: S
authors.lastname: Eichinger
authors.forename: S V
authors.initials: SV
authors.lastname: Seremetis
authors.forename: C S
authors.initials: CS
authors.lastname: Rabkin
authors.forename: F J
authors.initials: FJ
authors.lastname: Yellin
authors.forename: P S
authors.initials: PS
authors.lastname: Rosenberg
authors.forename: L M
authors.initials: LM
authors.lastname: Aledort
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000209:etiology* / Q000276:immunology / Q000401:mortality; D000328:Adult; D015496:CD4-Positive T-Lymphocytes; D015331:Cohort Studies; D005169:Factor VIII / Q000592:standards* / Q000627:therapeutic use*; D005434:Flow Cytometry; D005500:Follow-Up Studies; D006467:Hemophilia A / Q000150:complications* / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007958:Leukocyte Count; D011237:Predictive Value of Tests; D012307:Risk Factors
chemical_list: D005169:Factor VIII